Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 9 |
NetGPI | no | yes: 0, no: 9 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005730 | nucleolus | 5 | 1 |
GO:0005930 | axoneme | 2 | 1 |
GO:0043226 | organelle | 2 | 1 |
GO:0043228 | non-membrane-bounded organelle | 3 | 1 |
GO:0043229 | intracellular organelle | 3 | 1 |
GO:0043232 | intracellular non-membrane-bounded organelle | 4 | 1 |
GO:0110165 | cellular anatomical entity | 1 | 1 |
Related structures:
AlphaFold database: E9B734
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 131 | 135 | PF00656 | 0.284 |
CLV_PCSK_SKI1_1 | 130 | 134 | PF00082 | 0.480 |
CLV_PCSK_SKI1_1 | 85 | 89 | PF00082 | 0.527 |
CLV_PCSK_SKI1_1 | 96 | 100 | PF00082 | 0.552 |
CLV_Separin_Metazoa | 41 | 45 | PF03568 | 0.465 |
DEG_APCC_DBOX_1 | 100 | 108 | PF00400 | 0.500 |
DEG_APCC_DBOX_1 | 38 | 46 | PF00400 | 0.454 |
DOC_CYCLIN_RxL_1 | 82 | 92 | PF00134 | 0.542 |
DOC_MAPK_gen_1 | 130 | 139 | PF00069 | 0.534 |
DOC_MAPK_gen_1 | 37 | 45 | PF00069 | 0.467 |
DOC_PP1_RVXF_1 | 165 | 171 | PF00149 | 0.447 |
DOC_PP4_FxxP_1 | 4 | 7 | PF00568 | 0.432 |
LIG_14-3-3_CanoR_1 | 167 | 171 | PF00244 | 0.507 |
LIG_14-3-3_CanoR_1 | 72 | 78 | PF00244 | 0.505 |
LIG_14-3-3_CanoR_1 | 9 | 14 | PF00244 | 0.532 |
LIG_Actin_WH2_2 | 10 | 28 | PF00022 | 0.546 |
LIG_APCC_ABBA_1 | 43 | 48 | PF00400 | 0.527 |
LIG_BIR_II_1 | 1 | 5 | PF00653 | 0.514 |
LIG_Clathr_ClatBox_1 | 50 | 54 | PF01394 | 0.320 |
LIG_FHA_1 | 72 | 78 | PF00498 | 0.507 |
LIG_FHA_1 | 89 | 95 | PF00498 | 0.336 |
LIG_FHA_2 | 22 | 28 | PF00498 | 0.548 |
LIG_LIR_Apic_2 | 2 | 7 | PF02991 | 0.471 |
LIG_LIR_Gen_1 | 75 | 86 | PF02991 | 0.432 |
LIG_LIR_Nem_3 | 75 | 81 | PF02991 | 0.424 |
LIG_PDZ_Class_1 | 166 | 171 | PF00595 | 0.501 |
LIG_SH2_CRK | 84 | 88 | PF00017 | 0.569 |
LIG_SH2_STAP1 | 31 | 35 | PF00017 | 0.523 |
LIG_SH2_STAT3 | 46 | 49 | PF00017 | 0.561 |
LIG_UBA3_1 | 77 | 85 | PF00899 | 0.504 |
MOD_CK1_1 | 110 | 116 | PF00069 | 0.625 |
MOD_CK1_1 | 12 | 18 | PF00069 | 0.493 |
MOD_CK1_1 | 151 | 157 | PF00069 | 0.272 |
MOD_CK1_1 | 56 | 62 | PF00069 | 0.563 |
MOD_CK1_1 | 71 | 77 | PF00069 | 0.385 |
MOD_CK1_1 | 90 | 96 | PF00069 | 0.306 |
MOD_CK2_1 | 21 | 27 | PF00069 | 0.561 |
MOD_GlcNHglycan | 109 | 112 | PF01048 | 0.584 |
MOD_GSK3_1 | 128 | 135 | PF00069 | 0.330 |
MOD_GSK3_1 | 151 | 158 | PF00069 | 0.520 |
MOD_GSK3_1 | 67 | 74 | PF00069 | 0.463 |
MOD_NEK2_1 | 107 | 112 | PF00069 | 0.604 |
MOD_NEK2_1 | 11 | 16 | PF00069 | 0.488 |
MOD_PIKK_1 | 110 | 116 | PF00454 | 0.600 |
MOD_PIKK_1 | 151 | 157 | PF00454 | 0.523 |
MOD_PK_1 | 9 | 15 | PF00069 | 0.597 |
MOD_PKA_2 | 71 | 77 | PF00069 | 0.470 |
MOD_Plk_1 | 56 | 62 | PF00069 | 0.539 |
MOD_Plk_2-3 | 128 | 134 | PF00069 | 0.526 |
MOD_Plk_4 | 12 | 18 | PF00069 | 0.500 |
MOD_Plk_4 | 132 | 138 | PF00069 | 0.481 |
MOD_SUMO_for_1 | 20 | 23 | PF00179 | 0.547 |
TRG_DiLeu_BaEn_1 | 103 | 108 | PF01217 | 0.540 |
TRG_ENDOCYTIC_2 | 84 | 87 | PF00928 | 0.534 |
TRG_Pf-PMV_PEXEL_1 | 120 | 124 | PF00026 | 0.482 |
TRG_Pf-PMV_PEXEL_1 | 96 | 100 | PF00026 | 0.573 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1IHH3 | Leptomonas seymouri | 52% | 100% |
A0A0S4JTH6 | Bodo saltans | 23% | 97% |
A0A1X0P528 | Trypanosomatidae | 27% | 100% |
A0A422NCM8 | Trypanosoma rangeli | 27% | 100% |
A4HNH0 | Leishmania braziliensis | 68% | 100% |
C9ZYE2 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 23% | 100% |
E9AFY1 | Leishmania major | 90% | 100% |
Q25302 | Leishmania infantum | 89% | 100% |